Literature DB >> 11732118

IgG-Fc receptors and the clinical relevance of their polymorphisms.

M de Haas1.   

Abstract

Receptors for the Fc part of IgG form the bridge between immune complexes, antibodies and blood cells. Besides phagocytes, such as granulocytes and monocytes, also lymphocytes and platelets express members of the large family of IgG-Fc receptors or Fc gamma Rs. Three main classes of leukocyte Fc gamma Rs can be distinguished: Fc gamma RI, Fc gamma RII and Fc gamma RIII. Depending on the type of intracellular domain of the leukocyte Fc gamma Rs, interaction of a cell with an antibody-sensitized particle will induce either an activating signal (leading to phagocytosis, degranulation or toxic oxygen formation) or, in case of Fc gamma RIIb, an inhibiting signal. The inhibiting role of Fc gamma RIIb has long been thought to be only important for B-cell responses, however, recently it has been indicated that Fc gamma RIIb may have a much broader role in immune response, also regulating responses of phagocytes. In general, leukocyte Fc gamma Rs have high affinity for IgG1 and IgG3 subclasses. However, the affinity for the various IgG subclasses is influenced by receptor polymorphisms encoded by single nucleotide polymorphisms of the Fc gamma RIIa and Fc gamma RIIIa and Fc gamma RIIIb encoding genes. Because these subtle Fc gamma R changes determine the level of clearance of immune complexes, associations between Fc gamma R isoforms and disease risks have been investigated and also indicated as discussed in this review. Next to the leukocyte Fc gamma Rs, an IgG transport receptor, FcRn (neonatal Fc receptor) has been described. This receptor seems to be important for placental IgG transport and for IgG plasma level homeostasis. FcRn is expressed by endothelial cells and hepatocytes and functions in these cells as a receptor rescuing IgG from destruction, thereby increasing IgG half life. Also blood cells express FcRn and the exact role of FcRn in these cells is still to determined. Thus, although a lot is known, questions on the exact pattern of expression of the IgG receptors and their role in immune response still remain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732118

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  9 in total

1.  Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease.

Authors:  Shoichiro Taniuchi; Midori Masuda; Masayuki Teraguchi; Yumiko Ikemoto; Yutaka Komiyama; Hakuo Takahashi; Minoru Kino; Yohnosuke Kobayashi
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

2.  Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors.

Authors:  Yin Luo; Zhaojiang Lu; Stephen W Raso; Clifford Entrican; Bruce Tangarone
Journal:  MAbs       Date:  2009-09-24       Impact factor: 5.857

3.  Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.

Authors:  Branda T Hu; Xinhong Yu; Thomas R Jones; Carol Kirch; Sarah Harris; Stephen W Hildreth; Dace V Madore; Sally A Quataert
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

4.  Immunological status in the aetiology of recurrent otitis media with effusion: serum immunoglobulin levels, functional mannose-binding lectin and Fc receptor polymorphisms for IgG.

Authors:  Masja Straetemans; Selma P Wiertsema; Elisabeth A M Sanders; Ger T Rijkers; Kees Graamans; Bert van der Baan; Gerhard A Zielhuis
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

Review 5.  Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Authors:  Mohammad Tabrizi; Gadi Gazit Bornstein; Hamza Suria
Journal:  AAPS J       Date:  2009-11-19       Impact factor: 4.009

6.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

7.  Association of TNF and FcγRΙΙΙA gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients.

Authors:  Konstantinos Papamichael; Maria Gazouli; Christos Karakoidas; Ioanna Panayotou; Eleftheria Roma-Giannikou; Gerassimos J Mantzaris
Journal:  Ann Gastroenterol       Date:  2011

8.  Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept.

Authors:  Adam Walker; Chun-Wa Chung; Margarete Neu; Manish Burman; Thil Batuwangala; Gavin Jones; Chi-Man Tang; Michael Steward; Michael Mullin; Nadia Tournier; Alan Lewis; Justyna Korczynska; Vicky Chung; Ian Catchpole
Journal:  J Biol Chem       Date:  2016-01-04       Impact factor: 5.157

Review 9.  Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis.

Authors:  Cristina Membrive Jiménez; Cristina Pérez Ramírez; Almudena Sánchez Martín; Sayleth Vieira Maroun; Salvador Antonio Arias Santiago; María Del Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  J Pers Med       Date:  2021-04-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.